Glucocorticoid-loaded pH/ROS dual-responsive nanoparticles alleviate joint destruction by downregulating the NF-κB signaling pathway
Source abstract
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease causing severe symptoms that are difficult to treat. Nano-drug delivery system is recognized as a promising strategy for management of RA. However, how to thoroughly release payloads from nanoformulations and synergistic therapy of RA needs to be further investigated. To address this issue, a pH and reactive oxygen species (ROS) dual-responsive, methylprednisolone (MPS)-loaded and arginine-glycine-aspartic acid (RGD)-modified nanoparticles (NPs) was fabricated using phytochemical and ROS-responsive moiety co-modified α-cyclodextrin (α-CD) as a carrier. In vitro and in vivo experiments verified that the pH/ROS dual-responsive nanomedicine could be efficiently internalized by activated macrophages and synovial cells, and the released MPS could promote transformation of M1-type macrophages into M2 phenotype, thereby down-regulating pro-inflammatory cytokines. In vivo experiments demonstrated that the pH/ROS dual-responsive nanomedicine was remarkably accumulated in the inflamed joints of mice with collagen-induced arthritis (CIA). The accumulated nanomedicine could obviously relieve joint swelling and cartilage destruction without obvious adverse effects. Importantly, the expression of interleukin-6 and tumor necrosis factor-α in the joints of CIA mice were significantly inhibited by the pH/ROS dual-responsive nanomedicine in comparison with free drug and non-targeted counterparts. In addition, the expression of the NF-κB signaling pathway molecule P65 was also significantly decreased by nanomedicine-treatment. Our results reveal that MPS-loaded pH/ROS dual-responsive NPs can effectively alleviate joint destruction via down-regulation of the NF-κB signaling pathway. STATEMENT OF SIGNIFICANCE: Nanomedicine is recognized as an attractive method for the targeting treatment of rheumatoid arthritis (RA). To thorough release of payloads from nanoformulations and synergistic therapy of RA, herein, a phytochemical and ROS-responsive moiety co-modified α-cyclodextrin was used as a pH/ROS dual-responsive carrier to encapsulate methylprednisolone to manage RA. The fabricated nanomedicine can effectively release its payloads under pH and/or ROS microenvironment, and the released drugs dramatically promote transformation of M1-type macrophages into M2 phenotype to reduce the release of pro-inflammatory cytokines. The prepared nanomedicine also obviously decreased the NF-κB signaling pathway molecule P65 expression in the joints, thereby down-regulating pro-inflammatory cytokines expression to alleviate joint swelling and cartilage destruction. We provided a candidate for the targeting treatment of RA.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. One year in review 2017: pathogenesis of rheumatoid arthritis
2. Novel treatment strategies in rheumatoid arthritis10.1016/S0140-6736(17)31491-5 ↗
3. One year in review 2018: pathogenesis of rheumatoid arthritis
4. T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis10.1016/j.intimp.2019.03.008 ↗
5. The many facets of macrophages in rheumatoid arthritis10.1016/j.bcp.2019.03.029 ↗
6. Managing macrophages in rheumatoid arthritis by reform or removal10.1007/s11926-012-0272-4 ↗
7. Targeted therapy of rheumatoid arthritis via macrophage repolarization10.1080/10717544.2021.2000679 ↗
8. Efficacy of Xixiancao (Herba Siegesbeckiae Orientalis) on interactions between nuclear factor kappa-B and inflammatory cytokines in inflammatory reactions of rat synovial cells induced by sodium urate
9. Panaxynol induces fibroblast-like synovial cell apoptosis, inhibits proliferation and invasion through TLR4/NF-kappaB pathway to alleviate rheumatoid arthritis10.1016/j.intimp.2021.108321 ↗
10. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-alpha secretion10.1007/s000110050222 ↗
11. Targets of glucocorticoid action on TNF-alpha release by macrophages10.1007/PL00012387 ↗
12. Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis10.1136/annrheumdis-2022-222338 ↗
13. An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis10.1080/14740338.2019.1615052 ↗
14. The multiple facets of glucocorticoid action in rheumatoid arthritis10.1038/nrrheum.2012.166 ↗
15. Nanomedicine - advantages for their use in rheumatoid arthritis theranostics10.1016/j.jconrel.2019.11.008 ↗
16. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy10.1016/j.jconrel.2019.04.027 ↗
17. Reactive oxygen species-regulating strategies based on nanomaterials for disease treatment10.1002/advs.202002797 ↗
18. Rheumatoid arthritis microenvironment insights into treatment effect of nanomaterials10.1016/j.nantod.2021.101358 ↗
19. Reactive oxygen species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
20. Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review10.1016/j.autrev.2019.102397 ↗
21. HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis10.1038/s41467-019-12163-z ↗
22. Au@polydopamine nanoparticles/tocilizumab composite as efficient scavengers of oxygen free radicals for improving the treatment of rheumatoid arthritis10.1016/j.msec.2020.111434 ↗
23. Synergistic oxygen generation and reactive oxygen species scavenging by manganese ferrite/ceria co-decorated nanoparticles for rheumatoid arthritis treatment10.1021/acsnano.8b08785 ↗
24. ROS-responsive berberine polymeric micelles effectively suppressed the inflammation of rheumatoid arthritis by targeting mitochondria
25. Reactive oxygen species-responsive dendritic cell-derived exosomes for rheumatoid arthritis10.1016/j.actbio.2021.04.026 ↗
26. Construction of a pH-responsive, ultralow-dose triptolide nanomedicine for safe rheumatoid arthritis therapy10.1016/j.actbio.2020.11.027 ↗
27. pH-sensitive polymeric micelles as the methotrexate carrier for targeting rheumatoid arthritis10.1007/s13233-020-8072-6 ↗
28. Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy
29. Modular acid-activatable acetone-based ketal-linked nanomedicine by dexamethasone prodrugs for enhanced anti-rheumatoid arthritis with low side effects10.1021/acs.nanolett.9b05340 ↗
30. Cinnamaldehyde and eugenol attenuates collagen induced arthritis via reduction of free radicals and pro-inflammatory cytokines10.1016/j.phymed.2018.09.004 ↗
31. Cinnamaldehyde attenuates the progression of rheumatoid arthritis through down-regulation of PI3K/AKT signaling pathway10.1007/s10753-020-01246-5 ↗
32. Cinnamaldehyde suppresses NLRP3 derived IL-1beta via activating succinate/HIF-1 in rheumatoid arthritis rats10.1016/j.intimp.2020.106570 ↗
33. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway10.1016/j.jsps.2020.07.011 ↗
34. Anti-oxidant and anti-inflammatory effects of cinnamaldehyde and eugenol on mononuclear cells of rheumatoid arthritis patients10.1016/j.ejphar.2019.02.031 ↗
35. Reactive oxygen species-responsive dexamethasone-loaded nanoparticles for targeted treatment of rheumatoid arthritis via suppressing the iRhom2/TNF-alpha/BAFF signaling pathway10.1016/j.biomaterials.2019.119730 ↗
36. Antibiotic-loaded reactive oxygen species-responsive nanomedicine for effective management of chronic bacterial prostatitis10.1016/j.actbio.2022.02.044 ↗
37. Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment10.1080/10717544.2021.1963351 ↗
38. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles10.1186/s12951-019-0537-4 ↗
39. Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis10.4103/1735-5362.272534 ↗
40. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment
41. Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases10.1016/j.nano.2015.04.015 ↗
42. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
43. Targeting strategies for tissue-specific drug delivery10.1016/j.cell.2020.02.001 ↗
44. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery10.1039/C2CS35265F ↗
45. The role of neutrophils in rheumatic disease-associated vascular inflammation10.1038/s41584-021-00738-4 ↗
46. The dichotomized role for acid sensing ion channels in musculoskeletal pain and inflammation10.1016/j.neuropharm.2014.12.013 ↗
47. Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy10.1016/j.biomaterials.2019.119646 ↗
48. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors10.1016/j.intimp.2022.109095 ↗
49. Macrophage M1/M2 polarization10.1016/j.ejphar.2020.173090 ↗
50. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis10.3389/fimmu.2022.867260 ↗
51. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/NF-kappaB pathway10.1016/j.intimp.2017.01.010 ↗
52. Anti-rheumatoid arthritis effects of iridoid glucosides from Lamiophlomis rotata (Benth.) kudo on adjuvant-induced arthritis in rats by OPG/RANKL/NF-kappaB signaling pathways10.1016/j.jep.2020.113402 ↗
53. Difficult to treat' rheumatoid arthritis: current position and considerations for next steps10.1136/rmdopen-2022-002387 ↗